Base de dados : MEDLINE
Pesquisa : D20.888.065.970 [Categoria DeCS]
Referências encontradas : 1737 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 174 ir para página                         

  1 / 1737 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28950273
[Au] Autor:Rosman Y; Confino-Cohen R; Goldberg A
[Ad] Endereço:Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba, Israel.
[Ti] Título:Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol.
[So] Source:Int Arch Allergy Immunol;174(1):45-51, 2017.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Venom immunotherapy (VIT) is considered to be the gold standard treatment for patients with hymenoptera venom allergy. This treatment induces systemic reactions (SR) in a significant number of patients. OBJECTIVE: To evaluate the outcome of VIT in patients with known risk factors for VIT-induced SR and to compare rush VIT (RVIT) and conventional VIT (CVIT). METHODS: All of the patients who received VIT and had at least one of the following risk factors were included: current cardiovascular disease, uncontrolled asthma, high basal serum tryptase, current treatment with ß-blockers or angiotensin-converting enzyme inhibitors, and age >70 or <5 years. RESULTS: Sixty-four patients were included, and most of them (52; 81.5%) were allergic exclusively to bee venom. Thirty-five (54.7%) patients underwent RVIT and 29 CVIT. The incidence of patients who developed SR during the build-up phase was similar for RVIT and CVIT (25.7 and 27.5%, respectively; p = 1). However, the incidence of SR per injection was significantly higher in CVIT than in RVIT (5.6 and 2.75%, respectively; p = 0.01). Most reactions (79.1%) were mild, limited to the skin. Most of the patients (92.1%) reached the full maintenance dose of 100 µg. This dose was reached by a significantly larger number of patients receiving RVIT compared to CVIT (100 and 82.7%, respectively; p = 0.01). None of the patients experienced exacerbation of their concurrent chronic disease during VIT. CONCLUSION: VIT can be performed safely and efficiently in patients with risk factors for immunotherapy. In these patients RVIT appears to be safer and more efficient than CVIT.
[Mh] Termos MeSH primário: Alérgenos/administração & dosagem
Venenos de Abelha/administração & dosagem
Dessensibilização Imunológica/métodos
Venenos de Vespas/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Animais
Venenos de Abelha/imunologia
Pré-Escolar
Feminino
Seres Humanos
Himenópteros/imunologia
Masculino
Estudos Retrospectivos
Venenos de Vespas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Allergens); 0 (Bee Venoms); 0 (Wasp Venoms)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.1159/000479692


  2 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802697
[Au] Autor:Alvares DS; Wilke N; Ruggiero Neto J; Fanani ML
[Ad] Endereço:UNESP - São Paulo State University, IBILCE, Department of Physics, São José do Rio Preto, SP, Brazil.
[Ti] Título:The insertion of Polybia-MP1 peptide into phospholipid monolayers is regulated by its anionic nature and phase state.
[So] Source:Chem Phys Lipids;207(Pt A):38-48, 2017 Oct.
[Is] ISSN:1873-2941
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Polybia-MP1 or simply MP1 (IDWKKLLDAAKQIL-NH ) is a peptide with broad-spectrum bactericidal activity and a strong inhibitory effect against cancer cells. The aim of this work was to evaluate the effect of biophysical properties such as membrane texture and film thickness on MP1 interaction with neutral and anionic lipid membranes. For this purpose, we first explored the peptide's surface behavior. MP1 showed high surface activity, adsorbing onto bare air/aqueous interfaces up to higher surface pressures than the collapse pressure of MP1 Langmuir films. The MP1-lipid membrane interaction was studied using Langmuir phosphatidylcholine and phosphatidylserine (PS) monolayers as model membrane systems. PS was chosen since this negatively charged lipid was found predominantly on the outer leaflet of tumor cells, and it enhances MP1 activity for PS-containing membranes to a greater extent than for other negatively charged lipids. MP1 incorporated into anionic PS monolayers, which show a liquid-expanded (LE) phase or LE-liquid-condensed (LC) phase coexistence, up to lipid-packing densities higher than those of cell membranes. The mixed lipid/MP1 films were explored by Brewster angle microscopy and atomic force microscopy. MP1 partitioned preferentially into the LE phase state of PS films, and were thus excluded from the coexisting LC phase. This interaction had strong electrostatic bases: in pure water, the lipid-peptide interaction was strong enough to induce formation of reversible lipid-peptide 3D structures associated with the interface. MP1 incorporation into the LE phase was accompanied by a shift of the phase transition pressure to higher values and a thinning of the lipid film. These results showed a clear correlation between peptide penetration capacity and the presence or induction of the thin LE phase. This capacity to regulate membrane physical properties may be of relevance in the binding, incorporation and membrane selectivity of this promising antitumor peptide.
[Mh] Termos MeSH primário: Peptídeos Catiônicos Antimicrobianos/química
Peptídeos Catiônicos Antimicrobianos/metabolismo
Fosfolipídeos/química
Lipossomas Unilamelares/metabolismo
Venenos de Vespas/química
Venenos de Vespas/metabolismo
[Mh] Termos MeSH secundário: Ânions/química
Lipídeos de Membrana/química
Lipídeos de Membrana/metabolismo
Microscopia de Força Atômica
Concentração Osmolar
Propriedades de Superfície
Lipossomas Unilamelares/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anions); 0 (Antimicrobial Cationic Peptides); 0 (Membrane Lipids); 0 (Phospholipids); 0 (Unilamellar Liposomes); 0 (Wasp Venoms); 0 (polybia-MPI, Polybia paulista)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  3 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686638
[Au] Autor:Savi E; Incorvaia C; Boni E; Mauro M; Peveri S; Pravettoni V; Quercia O; Reccardini F; Montagni M; Pessina L; Ridolo E
[Ad] Endereço:Allergy Dept. Unit, G. Da Saliceto Hospital, AUSL, Piacenza, Italy.
[Ti] Título:Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study.
[So] Source:PLoS One;12(7):e0180270, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Venom immunotherapy (VIT) is highly effective in preventing allergic reactions to insect stings, but the appropriate venom must be used to achieve clinical protection. In patients with multiple positive results to venoms, molecular allergy diagnostics or CAP-inhibition may identify the causative venom. Concerning allergy to venom from Polistes spp. it has been proposed that only the European species P. dominulus should be used for VIT. However, this recommendation is not present in any international guideline. Using both laboratory and clinical data, we aimed to evaluate the reliability of this proposal. METHODS: We performed an in vitro study using CAP-inhibition to determine sensitization of 19 patients allergic to Polistes venom. The clinical study included 191 patients with positive tests to Polistes treated with VIT, 102 were treated with P. dominulus and 89 were treated with a mix of American Polistes (mAP). RESULTS: The difference in % of inhibition was significant concerning inhibition of P. dominulus sIgE by P. dominulus venom (79.8%) compared with inhibition by mAP venom (64.2%) and not significant concerning the inhibition of mAP sIgE by P. dominulus venom (80.1%) and by mAP venom (73.6%). Instead, the clinical protection from stings was not statistically different between the two kinds of venom. CONCLUSION: The data from CAP inhibition would suggest that the choice of either P. dominulus venom or mAP venom for VIT is appropriate in patients with CAP inhibition higher than 70%, but the clinical data show the same odds of protection from stings using for VIT P. dominulus or mAP venom.
[Mh] Termos MeSH primário: Alérgenos/administração & dosagem
Dessensibilização Imunológica/métodos
Hipersensibilidade Imediata/terapia
Mordeduras e Picadas de Insetos/terapia
Venenos de Vespas/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Alérgenos/química
Alérgenos/imunologia
Animais
Europa (Continente)
Seres Humanos
Hipersensibilidade Imediata/imunologia
Hipersensibilidade Imediata/fisiopatologia
Imunoglobulina E/sangue
Mordeduras e Picadas de Insetos/imunologia
Mordeduras e Picadas de Insetos/fisiopatologia
Meia-Idade
Especificidade da Espécie
Estados Unidos
Venenos de Vespas/química
Venenos de Vespas/imunologia
Vespas/química
Vespas/imunologia
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Allergens); 0 (Wasp Venoms); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180270


  4 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28501976
[Au] Autor:Tomsitz D; Brockow K
[Ad] Endereço:Department of Dermatology and Allergy Biederstein, Technische Universität München, Biedersteiner Straße 29, 80802, Munich, Germany.
[Ti] Título:Component Resolved Diagnosis in Hymenoptera Anaphylaxis.
[So] Source:Curr Allergy Asthma Rep;17(6):38, 2017 Jun.
[Is] ISSN:1534-6315
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: Hymenoptera anaphylaxis is one of the leading causes of severe allergic reactions and can be fatal. Venom-specific immunotherapy (VIT) can prevent a life-threatening reaction; however, confirmation of an allergy to a Hymenoptera venom is a prerequisite before starting such a treatment. Component resolved diagnostics (CRD) have helped to better identify the responsible allergen. RECENT FINDINGS: Many new insect venom allergens have been identified within the last few years. Commercially available recombinant allergens offer new diagnostic tools for detecting sensitivity to insect venoms. Additional added sensitivity to nearly 95% was introduced by spiking yellow jacket venom (YJV) extract with Ves v 5. The further value of CRD for sensitivity in YJV and honey bee venom (HBV) allergy is more controversially discussed. Recombinant allergens devoid of cross-reactive carbohydrate determinants often help to identify the culprit venom in patients with double sensitivity to YJV and HBV. CRD identified a group of patients with predominant Api m 10 sensitization, which may be less well protected by VIT, as some treatment extracts are lacking this allergen. The diagnostic gap of previously undetected Hymenoptera allergy has been decreased via production of recombinant allergens. Knowledge of analogies in interspecies proteins and cross-reactive carbohydrate determinants is necessary to distinguish relevant from irrelevant sensitizations.
[Mh] Termos MeSH primário: Alérgenos/imunologia
Anafilaxia/diagnóstico
Venenos de Abelha/imunologia
Himenópteros/imunologia
Venenos de Vespas/imunologia
[Mh] Termos MeSH secundário: Anafilaxia/imunologia
Animais
Reações Cruzadas
Seres Humanos
Imunoglobulina E/imunologia
Mordeduras e Picadas de Insetos/diagnóstico
Mordeduras e Picadas de Insetos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Allergens); 0 (Bee Venoms); 0 (Wasp Venoms); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170515
[St] Status:MEDLINE
[do] DOI:10.1007/s11882-017-0707-0


  5 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28497674
[Au] Autor:Silva D; Pereira AM; Santos N; Amaral L; Delgado L; Oude Elberink JN; Coimbra A
[Ad] Endereço:Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Porto, Portugal. E-mail: disolha@gmail.com Phone: 919 078 179. Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Portugal.
[Ti] Título:The Vespid Allergy Quality of Life Questionnaire - cultural adaptation and translation to Portuguese.
[So] Source:Eur Ann Allergy Clin Immunol;49(3):114-121, 2017 May.
[Is] ISSN:1764-1489
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Summary: A cross-cultural translation of the Vespid Allergy Quality of Life Questionnaire (VQLQ) to the Portuguese population (VQLQ-P) was performed, assessing its applicability in wasp and in non-beekeeper bee venom allergic patients. Additionally, we evaluated a Visual Analogue Scale (VAS) to estimate hymenoptera allergy interference with daily life. Cross-cultural translation was performed according to recommendations. The final VQLQ-P version, the Expectation of Outcome questionnaire (EoQ), EQ-5D and VAS were applied to wasp (n = 19) and non-beekeeper bee venom allergic patients (n = 30). VQLQ-P significantly correlated with EoQ, (r = 0.76, p < 0.01), EQ-5D (usual activities and anxiety / depression dimensions) and VAS, with a good internal consistency (Cronbach α = 0.88) in wasp allergic individuals. VQLQ-P and EoQ correlation was also high (r = 0.67, p < 0.01) in bee allergy. The VQLQ-P is a valuable tool to evaluate quality of life impairment in Portuguese hymenoptera venom allergic individuals.
[Mh] Termos MeSH primário: Hipersensibilidade/psicologia
Qualidade de Vida
Venenos de Vespas/imunologia
[Mh] Termos MeSH secundário: Adulto
Dessensibilização Imunológica
Feminino
Seres Humanos
Masculino
Meia-Idade
Inquéritos e Questionários
Tradução
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Wasp Venoms)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE


  6 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28417942
[Au] Autor:Teng ZW; Xiong SJ; Xu G; Gan SY; Chen X; Stanley D; Yan ZC; Ye GY; Fang Q
[Ad] Endereço:State Key Laboratory of Rice Biology & Key Laboratory of Agricultural Entomology of Ministry of Agriculture, Institute of Insect Sciences, Zhejiang University, Hangzhou 310058, China. tzwbat@126.com.
[Ti] Título:Protein Discovery: Combined Transcriptomic and Proteomic Analyses of Venom from the Endoparasitoid Cotesia chilonis (Hymenoptera: Braconidae).
[So] Source:Toxins (Basel);9(4), 2017 Apr 12.
[Is] ISSN:2072-6651
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Many species of endoparasitoid wasps provide biological control services in agroecosystems. Although there is a great deal of information on the ecology and physiology of host/parasitoid interactions, relatively little is known about the protein composition of venom and how specific venom proteins influence physiological systems within host insects. This is a crucial gap in our knowledge because venom proteins act in modulating host physiology in ways that favor parasitoid development. Here, we identified 37 possible venom proteins from the polydnavirus-carrying endoparasitoid by combining transcriptomic and proteomic analyses. The most abundant proteins were hydrolases, such as proteases, peptidases, esterases, glycosyl hydrolase, and endonucleases. Some components are classical parasitoid venom proteins with known functions, including extracellular superoxide dismutase 3, serine protease inhibitor and calreticulin. The venom contains novel proteins, not recorded from any other parasitoid species, including tolloid-like proteins, chitooligosaccharidolytic ß- -acetylglucosaminidase, FK506-binding protein 14, corticotropin-releasing factor-binding protein and vascular endothelial growth factor receptor 2. These new data generate hypotheses and provide a platform for functional analysis of venom components.
[Mh] Termos MeSH primário: Proteínas de Insetos/genética
Venenos de Vespas/genética
[Mh] Termos MeSH secundário: Animais
Feminino
Filogenia
Proteômica
RNA Mensageiro/metabolismo
Transcriptoma
Vespas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insect Proteins); 0 (RNA, Messenger); 0 (Wasp Venoms)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170803
[Lr] Data última revisão:
170803
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE


  7 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28398199
[Au] Autor:Nittner-Marszalska M; Kowal A; Szewczyk P; Guranski K; Ejma M
[Ad] Endereço:Department of Internal Diseases and Allergology, Wroclaw Medical University, Wroclaw, Poland.
[Ti] Título:Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe?
[So] Source:J Investig Allergol Clin Immunol;27(2):127-129, 2017.
[Is] ISSN:1018-9068
[Cp] País de publicação:Spain
[La] Idioma:eng
[Mh] Termos MeSH primário: Anafilaxia/terapia
Dessensibilização Imunológica/métodos
Mordeduras e Picadas de Insetos/terapia
Vasculite do Sistema Nervoso Central/complicações
Venenos de Vespas/administração & dosagem
Vespas/imunologia
[Mh] Termos MeSH secundário: Anafilaxia/diagnóstico
Anafilaxia/imunologia
Animais
Dessensibilização Imunológica/efeitos adversos
Avaliação da Deficiência
Feminino
Seres Humanos
Mordeduras e Picadas de Insetos/diagnóstico
Mordeduras e Picadas de Insetos/imunologia
Imagem por Ressonância Magnética
Meia-Idade
Segurança do Paciente
Fatores de Risco
Resultado do Tratamento
Vasculite do Sistema Nervoso Central/diagnóstico
Vasculite do Sistema Nervoso Central/tratamento farmacológico
Vasculite do Sistema Nervoso Central/imunologia
Venenos de Vespas/efeitos adversos
Venenos de Vespas/imunologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Wasp Venoms)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.18176/jiaci.0126


  8 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28380475
[Au] Autor:Fiedler C; Miehe U; Treudler R; Kiess W; Prenzel F
[Ad] Endereço:Division of Pediatric Pneumology and Allergy, University Hospital for Children and Adolescents, Leipzig, Germany.
[Ti] Título:Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines.
[So] Source:Int Arch Allergy Immunol;172(3):167-172, 2017.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Data on the long-term outcome of children after specific venom immunotherapy (VIT) are limited. Therefore, we assessed sting recurrence and anaphylaxis relapse rates as well as adherence to anaphylaxis guidelines with regard to the availability of emergency equipment and education status. METHODS: For this long-term survey, data of 311 children with a history of anaphylactic reactions to hymenoptera stings were collected by chart review. We included patients who were treated with a 3-year VIT between 1993 and 2009 and had completed a questionnaire. RESULTS: Forty of the 311 patients were included. Mean VIT duration was 3.1 years. Of the 40 patients included, 29 children (72.5%) received VIT with vespid venom, 9 with bee venom, and 2 patients with both venoms. During a mean follow-up period of 13 years, 20/40 patients (50%) suffered re-stings. Six of the 20 (30%) patients developed again anaphylactic symptoms (grade 1 n = 5, grade 3 n = 1); 2 were allergic to vespid and 4 to bee venom. Of the entire cohort, only 5/40 (12.5%) had appropriate emergency kits according to the guidelines of the European Academy of Allergy and Clinical Immunology. Among the patients who had emergency kits available, one third (5/15) felt uncertain about the correct application of the medication. Less than two thirds of our population (25/40) affirmed that they have been educated in emergency management. The vast majority (95%; 38/40) of our patients did not have allergy follow-ups after VIT completion. CONCLUSIONS: Anaphylactic relapses are not uncommon, and there are considerable deficits in the emergency management of patients. Hence, comprehensive standardized anaphylaxis education programs as well as regular follow-ups of the allergy status are crucial.
[Mh] Termos MeSH primário: Anafilaxia/prevenção & controle
Venenos de Abelha/imunologia
Dessensibilização Imunológica
Venenos de Vespas/imunologia
[Mh] Termos MeSH secundário: Adolescente
Anafilaxia/etiologia
Animais
Criança
Pré-Escolar
Feminino
Seres Humanos
Imunoglobulina E/sangue
Mordeduras e Picadas de Insetos/sangue
Mordeduras e Picadas de Insetos/complicações
Mordeduras e Picadas de Insetos/imunologia
Masculino
Cooperação do Paciente
Educação de Pacientes como Assunto
Guias de Prática Clínica como Assunto
Recidiva
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bee Venoms); 0 (Wasp Venoms); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE
[do] DOI:10.1159/000458707


  9 / 1737 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28299840
[Au] Autor:Qiu S; Zhu R; Zhao Y; An X; Jia F; Peng J; Ma Z; Zhu Y; Wang J; Su J; Wang Q; Wang H; Li Y; Wang K; Yan W; Wang R
[Ad] Endereço:Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Institute of Biochemistry and Molecular Biology, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, China.
[Ti] Título:Antimicrobial activity and stability of protonectin with D-amino acid substitutions.
[So] Source:J Pept Sci;23(5):392-402, 2017 May.
[Is] ISSN:1099-1387
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The misuse and overuse of antibiotics result in the emergence of resistant bacteria and fungi, which make an urgent need of the new antimicrobial agents. Nowadays, antimicrobial peptides have attracted great attention of researchers. However, the low physiological stability in biological system limits the application of naturally occurring antimicrobial peptides as novel therapeutics. In the present study, we synthesized derivatives of protonectin by substituting all the amino acid residues or the cationic lysine residue with the corresponding D-amino acids. Both the D-enantiomer of protonectin (D-prt) and D-Lys-protonectin (D-Lys-prt) exhibited strong antimicrobial activity against bacteria and fungi. Moreover, D-prt showed strong stability against trypsin, chymotrypsin and the human serum, while D-Lys-prt only showed strong stability against trypsin. Circular dichroism analysis revealed that D-Lys-prt still kept typical α-helical structure in the membrane mimicking environment, while D-prt showed left hand α-helical structure. In addition, propidium iodide uptake assay and bacteria and fungi killing experiments indicated that all D-amino acid substitution or partially D-amino acid substitution analogs could disrupt the integrity of membrane and lead the cell death. In summary, these findings suggested that D-prt and D-Lys-prt might be promising candidate antibiotic agents for therapeutic application against resistant bacteria and fungi infection. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Anti-Infecciosos/síntese química
Peptídeos Catiônicos Antimicrobianos/síntese química
Bactérias/efeitos dos fármacos
Fungos/efeitos dos fármacos
Venenos de Vespas/química
[Mh] Termos MeSH secundário: Substituição de Aminoácidos
Anti-Infecciosos/química
Anti-Infecciosos/farmacologia
Peptídeos Catiônicos Antimicrobianos/química
Peptídeos Catiônicos Antimicrobianos/farmacologia
Permeabilidade da Membrana Celular/efeitos dos fármacos
Dicroísmo Circular
Desenho de Drogas
Testes de Sensibilidade Microbiana
Modelos Moleculares
Estrutura Secundária de Proteína
Relação Estrutura-Atividade
Venenos de Vespas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Antimicrobial Cationic Peptides); 0 (Wasp Venoms)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE
[do] DOI:10.1002/psc.2989


  10 / 1737 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28283430
[Au] Autor:Qian C; Liang D; Liu Y; Wang P; Kausar S; Wei G; Zhu B; Wang L; Liu C
[Ad] Endereço:College of Life Sciences, Anhui Agricultural University, 130 Changjiang West Road, Hefei, 230036, PR China.
[Ti] Título:Identification of a small pacifastin protease inhibitor from Nasonia vitripennis venom that inhibits humoral immunity of host (Musca domestica).
[So] Source:Toxicon;131:54-62, 2017 Jun 01.
[Is] ISSN:1879-3150
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Nasonia vitripennis is an important natural enemy of many flies. Pacifastin protease inhibitors (PPIs) play an important role in development and innate immunity of insects. In this study, cDNA sequences of a small pacifastin protease inhibitor in N. vitripennis (NvSPPI) was characterized and its open reading frame (ORF) contains 243bp. Real-time quantitative PCR (RT-qPCR) results revealed that NvSPPI mRNA were detected specifically in the venom apparatus, while they were expressed at low levels in other tissues tested. In the venom apparatus, NvSPPI transcript was highly expressed on the fourth day post eclosion and then declined gradually. The NvSPPI gene was recombinantly expressed utilizing a pGEX-4T-2 vector, and the recombinant products fused with glutathione S-transferase were purified. Inhibition of recombinant GST-NvSPPI to three serine protease inhibitors (trypsin, chymotrypsin, and protease K) were tested and results showed that recombinant NvSPPI could inhibit the activity of trypsin. Meanwhile, we evaluated the influence of the recombinant GST-NvSPPI on the phenoloxidase (PO) activity and prophenoloxidase (PPO) activation of hemolymph from a host pupa, Musca domestica. Results showed PPO activation in host hemolymph was inhibited by recombinant NvSPPI; however, there was no significant inhibition on the PO activity. Our results suggested that NvSPPI could inhibit PPO activation in host hemolymph and trypsin activity in vitro.
[Mh] Termos MeSH primário: Moscas Domésticas/efeitos dos fármacos
Imunidade Humoral/efeitos dos fármacos
Proteínas/isolamento & purificação
Inibidores de Serino Proteinase/isolamento & purificação
Venenos de Vespas/química
[Mh] Termos MeSH secundário: Animais
Catecol Oxidase/metabolismo
Precursores Enzimáticos/metabolismo
Feminino
Glutationa Transferase/metabolismo
Hemolinfa/metabolismo
Masculino
Monofenol Mono-Oxigenase/metabolismo
Fases de Leitura Aberta
Proteínas/farmacologia
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Proteínas Recombinantes/metabolismo
Inibidores de Serino Proteinase/farmacologia
Vespas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Precursors); 0 (Proteins); 0 (RNA, Messenger); 0 (Recombinant Proteins); 0 (Serine Proteinase Inhibitors); 0 (Wasp Venoms); 0 (pacifastin); EC 1.10.3.- (pro-phenoloxidase); EC 1.10.3.1 (Catechol Oxidase); EC 1.14.18.1 (Monophenol Monooxygenase); EC 2.5.1.18 (Glutathione Transferase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170312
[St] Status:MEDLINE



página 1 de 174 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde